Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.

Abstract

OBJECTIVE Risedronate is a bisphosphonate used in the treatment of osteoporosis. It has a strong effect in inhibiting osteoclast activity. The primary objective of this study was to evaluate the effectiveness and adverse events of two different forms of risedronate (5 mg and 35 mg) using a rapid biochemical marker for comparison of C-terminal telopeptide… (More)

Topics

Cite this paper

@article{Ilter2006EfficacyAA, title={Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.}, author={Elif Ece Ilter and Hakan Mete Karalok and E Can Tufekci and Okan Zafer Batur}, journal={Climacteric : the journal of the International Menopause Society}, year={2006}, volume={9 2}, pages={129-34} }